Frederique Ph.D. Menzaghi - 01 Feb 2024 Form 4 Insider Report for Cara Therapeutics, Inc. (CARA)

Role: CHIEF SCIENTIFIC OFF,SVP-R&D
Signature: /s/ Darren DeStefano, Attorney-in-Fact
Issuer symbol: CARA
Transactions as of: 01 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 05 Feb 2024, 16:28:07 UTC
Previous filing: 27 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CARA	Common Stock	Award	$0	+13,500	+8.8%	$0.000000	167,247	01 Feb 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Frederique Ph.D. Menzaghi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.

Content

Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.